01 — At a Glance
The Pharma House That Decided to Eat Acquisitions for Breakfast
- 52-Week High / Low₹1,059 / ₹795
- Q3 FY26 Revenue₹6,864 Cr
- Q3 FY26 PAT₹1,103 Cr
- Q3 FY26 EPS₹10.36
- 9M FY26 Revenue (YTD)₹19,561 Cr
- Book Value₹251
- Price to Book3.63x
- Dividend Yield1.20%
- Debt / Equity0.38x
- TTM EPS₹49.1
Auditor’s Opening Note: Zydus Lifesciences closed Q3 FY26 with ₹6,864 crore revenue (+30.3% YoY), ₹1,103 crore PAT (+7.7% YoY), and EBITDA margin at 26.5% despite acquisition digestion. The stock returned -9.57% in the last six months. Meanwhile, management guided “23% plus EBITDA margin in Q4 even with Revlimid rolloff” and specialty launches worth billions incoming. Auditor’s question: why is the market not running at this stock? Because acquisitions scare retail. Because Revlimid is disappearing. Because excitement sells, boring excellence doesn’t.
02 — Introduction
The House that Built Itself Into an Aspiring Specialty Pharma Player
Meet Zydus Lifesciences. Once upon a time — specifically, 1995 — it was restructured into Cadila Healthcare as a branded generics play on India’s healthcare boom. Three decades of patient compounding later, it’s run by a third-generation promoter (Sharvil Patel, ~75% stake), owns 419 US FDA approvals, ranks 5th in the US generics market, and just spent ₹9,636 crore on debt to fund acquisitions because apparently “being a ₹5,700+ crore revenue pharma house” wasn’t enough. Now, in Q3 FY26, they’re running a portfolio that looks like a Frankenstein: domestic branded generics, US base generics, specialty oncology via Sentynl, biosimilars (nivolumab launched Jan 2026, pembrolizumab in trials), consumer wellness (Comfort Click acquisition of £239 million, all-in Q3), medical devices (Amplitude Surgical), vaccines (Typhoid, Rabies), and active drug master filings for API players. It’s chaos. Beautiful, well-executed chaos.
Revlimid, once a $40-50 crore yearly gift, has tapered to irrelevance. The company has mitigated this by growing US generics by 11% volume despite a 1% market growth. Industrial base is strong. India formulations outperformed market by 14% growth. And now they’re launching specialty products on a schedule that would tire a normal company. The concall was 90 minutes of management explaining why a ₹9,636 crore debt increase is actually “comfortable” and why specialty launches in FY27 will drive “meaningful step-change in profitability.” Let’s parse the chaos and decide if it’s controlled brilliance or a betting spree.
Concall Note (Feb 2026): “Excluding acquisitions, the base sustained double-digit growth with all key businesses delivering ahead of expectations.” — Management. Translation: even if you ignore ₹9,636 crore spent on bolt-ons, we grew organically in double digits. Not terrible, for a company juggling four continents.
03 — Business Model: Complexity Theatre
Five Parallel Universes, One Holding Company.
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
